Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Mentice ABFRA:MN2 -4.15%75 FCF Margin % is 7.75% as of Jun. 2026, which is 812% above its 10-year median of 0.85. GuruFocus rates FRA:MN2 with a GF Score™ of 75/100 and a GF Value™ of €1.91 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 814 Medical Devices & Instruments companies, Mentice AB ranks better than 61.06% on this metric.
FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Mentice AB's Free Cash Flow for the
three
months ended in Jun. 2026 was €0.56 Mil. Mentice AB's Revenue for the
three
months ended in Jun. 2026 was €7.26 Mil. Therefore, Mentice AB's FCF Margin % for the quarter that ended in Jun. 2026 was 7.75%.
The historical rank and industry rank for Mentice AB's FCF Margin % or its related term are showing as below:
FRA:MN2'
s FCF Margin % Range Over the Past 10 Years
Min: -27.62 Med: 0.85 Max: 10.79
Current: 4.33
During the past 9 years, the highest FCF Margin % of Mentice AB was 10.79%. The lowest was -27.62%. And the median was 0.85%.
FRA:MN2's FCF Margin % is ranked better than 61.06% of 814
companies
in the Medical Devices & Instruments industry
Industry Median: -0.72
vs FRA:MN2: 4.33
The historical data trend for Mentice AB's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Mentice AB's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mentice AB FCF Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Mentice AB's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Mentice AB's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mentice AB (FRA:MN2) has a FCF Margin % of 7.75% as of Jun. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Mentice AB and its competitors. This is 812% above median its historical median of 0.85. According to the industry distribution chart, Mentice AB ranks #317 out of 814 companies in the Medical Devices & Instruments industry, placing it in the top 38.9%.
Is Mentice AB's FCF Margin % too high?
Mentice AB's current FCF Margin % of 7.75% is 812% above median its 10-year median of 0.85. Based on the distribution chart, Mentice AB ranks #317 out of 814 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Mentice AB has a GF Score™ of 75/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Mentice AB's FCF Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Mentice AB ranks #317 out of 814 companies for FCF Margin %. This puts Mentice AB in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Medical Devices & Instruments company?
A good FCF Margin % depends on the Medical Devices & Instruments industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Mentice AB and its competitors. Mentice AB's current FCF Margin % is 7.75%, which is 812% above median its own 10-year median of 0.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mentice AB stock overvalued right now?
Based on GuruFocus' analysis, Mentice AB (FRA:MN2) is currently considered Significantly Undervalued. The stock's GF Value™ is €1.91, compared to a current price of €1.27 — trading 33.5% below its estimated fair value. The current FCF Margin % is 7.75%, which is 812% above median its 10-year median of 0.85. Mentice AB's overall GF Score™ is 75/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Mentice AB (FRA:MN2), the current FCF Margin % is 7.75% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Mentice AB (FRA:MN2) Overvalued in 2026?
Based on GuruFocus' analysis, Mentice AB stock appears to be undervalued.
The current stock price of €1.27 is trading 33.5% below its estimated GF Value™ of €1.91.
GuruFocus considers Mentice AB to be Significantly Undervalued.
Key valuation signals for FRA:MN2:
FCF Margin %: 7.75% (812% above median its 10-year median of 0.85)
GF Value™: €1.91 vs. price of €1.27 (33.5% below fair value)
No single metric tells the full story. See the FRA:MN2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Mentice AB is a provider of software and hardware simulation solutions for image guided interventional therapies, offering proficiency based simulation solutions that help healthcare professionals acquire, retain, and enhance procedural skills, improving productivity and outcomes. Its solutions are scientifically validated and developed for healthcare providers and the medical device industry. Neurovascular, cardiovascular, and peripheral interventions are covered. Mentice operates in two segments: Medical Device Industry (MDI), providing end-to-end solutions supporting development and launch of interventional therapies, and Healthcare Systems (HCS). Product areas include Mentice VIST, Physical Sim, Mentice Live, and Ankyras. It operates in EMEA, APAC, and the Americas.
75GF Score
Get the complete analysis for FRA:MN2
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:MN2 has been successfully added to your 
